Do GLP-1 Agonists Slow Progression of Renal Disease in Patients with Type 2 Diabetes?

In a randomized trial, semaglutide accomplished this goal, but its clinical benefit was driven largely by fewer cardiovascular-related deaths.

For patients with type 2 diabetes, several glucagon-like peptide-1 (GLP-1) agonists are U.S. FDA-approved to lower cardiovascular (CV) risk but not specifically to slow progression of chronic kidney disease (CKD). To explore this potential indication, industry-sponsored researchers randomized 3500 patients (mean age, 67) with type 2 diabetes and CKD to receive either subcutaneous semaglutide or placebo. CKD was defined as estimated glomerular filtration rate (eGFR) of 25 to 75 mL/minute/1.73 m², plus albuminuria.

At baseline, nearly all patients were taking angiotensin–converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers; very few were taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors or finerenone (two drugs approved …

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Do GLP-1 Agonists Slow Progression of Renal Disease in Patients with Type 2 Diabetes?

Topics

Reviewing Author